Equity
Retained Earnings
Vertex Pharmaceuticals Retained Earnings increased by 7.6% to $14.59B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 42.3%, from $10.25B to $14.59B. Over 5 years (FY 2020 to FY 2025), Retained Earnings shows an upward trend with a 73.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryProfitability
SignalHigher is better
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026May 5, 2026
How to read this metric
A steady increase indicates consistent profitability and successful reinvestment of earnings into the business.
Detailed definition
This represents the cumulative net income earned by the company since inception, minus any dividends paid to shareholder...
Peer comparison
High for mature, profitable biotech firms; lower for early-stage companies focused on aggressive R&D spending.
Metric ID:
retained_earningsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.58B | $2.43B | $3.20B | $3.96B | $4.77B | $5.70B | $6.52B | $7.22B | $8.14B | $9.17B | $10.14B | $11.24B | $7.65B | $8.69B | $9.61B | $10.25B | $11.29B | $12.37B | $13.56B | $14.59B |
| QoQ Change | — | +54.0% | +31.7% | +23.8% | +20.5% | +19.5% | +14.4% | +10.7% | +12.7% | +12.7% | +10.6% | +10.8% | -32.0% | +13.7% | +10.5% | +6.7% | +10.1% | +9.6% | +9.6% | +7.6% |
| YoY Change | — | — | — | — | +202.4% | +134.7% | +103.8% | +82.3% | +70.5% | +60.8% | +55.5% | +55.7% | -6.0% | -5.2% | -5.3% | -8.8% | +47.6% | +42.3% | +41.2% | +42.3% |
Range$1.58B – $14.59B
CAGR+59.7%
Avg YoY Growth+57.1%
Median YoY Growth+51.5%
Current Streak7 quarters growth
Retained Earnings at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's retained earnings?
- Vertex Pharmaceuticals (VRTX) reported retained earnings of $14.59B in Q1 2026.
- How has Vertex Pharmaceuticals's retained earnings changed year-over-year?
- Vertex Pharmaceuticals's retained earnings increased by 42.3% year-over-year, from $10.25B to $14.59B.
- What is the long-term trend for Vertex Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's retained earnings has grown at a 73.7% compound annual growth rate (CAGR), from $858.70M to $13.56B.
- What does retained earnings mean?
- The portion of net profits kept in the business rather than paid out as dividends.